CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor

Exclusion Criteria

• •Any of the following as this regimen may be harmful to a developing fetus or nursing child:
• •* Pregnant women
• •* Breast-feeding women
• •* Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception ( diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.)
• •Any of the following:
• •* Nitrosoureas or mitomycin =\< 6 weeks prior to study entry
• •* Other chemotherapy =\< 4 weeks prior to study entry
• •* Radiotherapy =\< 4 weeks prior to study entry
• •* Concurrent use of any other investigation agent
• •* Adverse events due to agents administered =\< 4 weeks prior to study entry
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to CCI-779
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, diabetes, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Known HIV-positive patients receiving combination anti-retroviral therapy
• •Prior chemotherapy for metastatic disease
• •* Exceptions:
• •* Patients with GIST who fail Gleevec are eligible
• •* Patients who have had adjuvant/neoadjuvant chemotherapy are also eligible
• •Known brain metastases
• •* Exception: Patients with treated brain metastatic disease with stable symptoms after treatment for \>= 1 month